keyword
MENU ▼
Read by QxMD icon Read
search

Cancer hematology oncology

keyword
https://www.readbyqxmd.com/read/27908537/the-unusual-association-between-neuroblastoma-and-gaucher-disease-case-report-and-review-of-the-literature
#1
Annalisa Madeo, Alberto Garaventa, Angela Rita Sementa, Chiara Suffia, Maja Di Rocco
Gaucher disease (GD) patients have an increased risk of cancer, in particular of hematological origin, while the association between GD and Neuroblastoma (NBL) has never been described. Here we report the case of an adolescent diagnosed with NBL, also presenting splenomegaly and persistent thrombocytopenia. The association with GD, suggested by the histological findings on bone marrow biopsy, was confirmed by enzymatic and genetic tests. The possible pathogenetic mechanisms are briefly reviewed. The evidence of this new association supports the necessity of further studies on GD comorbidities and the need of systematic data collection and analysis, potentially through an international registry...
November 23, 2016: Blood Cells, Molecules & Diseases
https://www.readbyqxmd.com/read/27900832/bromodomain-and-extraterminal-protein-inhibitors-in-pediatrics-a-review-of-the-literature
#2
REVIEW
Irene Jiménez, André Baruchel, François Doz, Johannes Schulte
The last few years have seen the identification of pharmacologic approaches to target bromodomain and extraterminal (BET) proteins for cancer treatment. These proteins have an essential role in gene transcription regulation by binding acetylated lysine residues on histone tails, activating gene transcription. BET inhibitors have been tested in preclinical models including pediatric malignancies and several adult clinical trials are ongoing. Since the development of new drugs in pediatric cancer has long lagged behind programs for adults, the aim of this review is to show the importance of these therapies in pediatric malignancies to support their development in pediatric oncology/hematology...
November 30, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27896440/a-phase-iii-open-label-randomized-multicenter-controlled-trial-of-oral-versus-intravenous-treosulfan-in-heavily-pretreated-recurrent-ovarian-cancer-a-study-of-the-north-eastern-german-society-of-gynecological-oncology-noggo
#3
Jalid Sehouli, Oliver Tomè, Desislava Dimitrova, Oumar Camara, Ingo Bernhard Runnebaum, Hans Werner Tessen, Beate Rautenberg, Radoslav Chekerov, Mustafa Zelal Muallem, Michael Patrick Lux, Tanja Trarbach, Gerald Gitsch
OBJECTIVE: In recurrent ovarian cancer (ROC), there is a high demand on effective therapies with a mild toxicity profile. Treosulfan is an alkylating agent approved as oral (p.o.) and intravenous (i.v.) formulation for the treatment of recurrent ovarian cancer. Data on safety and efficacy for either formulation are rare. For the first time we conducted a randomized phase III study comparing both formulations in women with ROC. METHODS: Patients having received at least two previous lines of chemotherapy were randomly assigned to one of two treatment arms: treosulfan i...
November 28, 2016: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/27886124/advances-in-cancer-immunotherapy-in-solid-tumors
#4
REVIEW
Smitha Menon, Sarah Shin, Grace Dy
Immunotherapy is heralded as one of the most important advances in oncology. Until recently, only limited immunotherapeutic options were available in selected immunogenic cancers like melanoma and renal cell carcinomas. Nowadays, there is an improved understanding that anti-tumor immunity is controlled by a delicate balance in the tumor microenvironment between immune stimulatory and immune inhibitory pathways. Either by blocking the inhibitory pathways or stimulating the activating pathways that regulate cytotoxic lymphocytes, anti-tumor immunity can be enhanced leading to durable anti-tumor responses...
November 24, 2016: Cancers
https://www.readbyqxmd.com/read/27868581/2016-updated-american-society-of-clinical-oncology-oncology-nursing-society-chemotherapy-administration-safety-standards-including-standards-for-pediatric-oncology
#5
Michael N Neuss, Terry R Gilmore, Kristin M Belderson, Amy L Billett, Tara Conti-Kalchik, Brittany E Harvey, Carolyn Hendricks, Kristine B LeFebvre, Pamela B Mangu, Kristen McNiff, MiKaela Olsen, Lisa Schulmeister, Ann Von Gehr, Martha Polovich
Purpose To update the ASCO/Oncology Nursing Society (ONS) Chemotherapy Administration Safety Standards and to highlight standards for pediatric oncology. Methods The ASCO/ONS Chemotherapy Administration Safety Standards were first published in 2009 and updated in 2011 to include inpatient settings. A subsequent 2013 revision expanded the standards to include the safe administration and management of oral chemotherapy. A joint ASCO/ONS workshop with stakeholder participation, including that of the Association of Pediatric Hematology Oncology Nurses and American Society of Pediatric Hematology/Oncology, was held on May 12, 2015, to review the 2013 standards...
November 21, 2016: Journal of Oncology Practice
https://www.readbyqxmd.com/read/27867951/red-cell-distribution-width-and-cancer
#6
REVIEW
Martina Montagnana, Elisa Danese
Red cell distribution width (RDW) is an index which primarily reflects impaired erythropoiesis and abnormal red blood cell survival. In last years the interest in this marker has considerably grown and now a lot of data are available indicating that this simple and inexpensive parameter is a strong and independent risk factor for death in the general population. Moreover, several investigations have been performed to investigate the role of RDW in cardiovascular and thrombotic disorders. Contrarily, there are relatively few reports focusing on RDW in the area of oncology and to date none review have been performed in this specific field...
October 2016: Annals of Translational Medicine
https://www.readbyqxmd.com/read/27858547/teams-and-teamwork-in-cancer-care-delivery-shared-mental-models-to-improve-planning-for-discharge-and-coordination-of-follow-up-care
#7
Jenna S Page, Lynne Lederman, Jamie Kelly, Maura M Barry, Ted A James
This article discusses the potential for shared mental models to improve teamwork during discharge planning and follow-up care. A 58-year-old inpatient on the hematology care unit of an academic medical center was discharged to his community after initial treatment of acute myeloid leukemia, without a clear plan for either discharge or follow-up. This case highlights the challenges faced by the primary oncology care team, the patient's community health-care team, the patient, and his caregiver, because a formal plan for follow-up care after discharge was not in place...
November 2016: Journal of Oncology Practice
https://www.readbyqxmd.com/read/27856600/tti-621-sirp%C3%AE-fc-a-cd47-blocking-innate-immune-checkpoint-inhibitor-with-broad-anti-tumor-activity-and-minimal-erythrocyte-binding
#8
Penka S Petrova, Natasja N Viller, Mark Wong, Xinli Pang, Gloria H Y Lin, Karen Dodge, Vien Chai, Hui Chen, Vivian Lee, Violetta House, Noel T Vigo, Debbie Jin, Tapfuma Mutukura, Marilyse Charbonneau, Tran Truong, Stéphane Viau, Lisa D Johnson, Emma Linderoth, Eric L Sievers, Saman Maleki Vareki, Rene Figueredo, Macarena Pampillo, James Koropatnick, Suzanne Trudel, Nathan Mbong, Liqing Jin, Jean C Y Wang, Robert A Uger
PURPOSE: The ubiquitously expressed transmembrane glycoprotein CD47 delivers an anti-phagocytic (do-not-eat) signal by binding signal-regulatory protein α (SIRPα) on macrophages. CD47 is over-expressed in cancer cells and its expression is associated with poor clinical outcomes. TTI 621 (SIRPαFc) is a fully human recombinant fusion protein that blocks the CD47:SIRPα-axis by binding to human CD47 and enhancing phagocytosis of malignant cells. Blockade of this inhibitory axis using TTI-621 has emerged as a promising therapeutic strategy to promote tumor cell eradication...
November 17, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27842503/the-validity-of-pediatric-cancer-diagnoses-in-a-population-based-general-cancer-registry-in-ontario-canada
#9
Sumit Gupta, Jason D Pole
BACKGROUND: Data from population-based cancer registries are increasingly used to conduct research and guide policy. However, few validation studies of cancer registry data have been conducted, particularly among children. We therefore aimed to determine the validity of pediatric diagnostic data in the Ontario Cancer Registry (OCR). METHODS: All children diagnosed with any malignancy between 2000-2011 in Ontario, Canada were identified through the Pediatric Oncology Group of Ontario Networked Information System (POGONIS), a pediatric cancer registry actively maintained by trained data managers, and linked to the OCR...
November 14, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27801310/-chinese-guidelines-for-diagnosis-and-treatment-of-acute-lymphoblastic-leukemia-2016
#10
(no author information available yet)
No abstract text is available yet for this article.
October 14, 2016: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://www.readbyqxmd.com/read/27784402/-research-progress-in-detection-of-malignant-hematologic-diseases-by-bio-electrochemistry-review
#11
Yu-Jie Wang, Bao-An Chen
Hematologic disease has become a common disease that produces harm and burdens to human individuals today, seriously threatening public health care. Particularly, the damage caused by malignant hematologic disease has been recognized by doctors and patients. However, low cure rate and high recurrence rate are the main issues when treating malignant hematologic disease by current methods. The survival rate could be significantly improved if the early metaphase diagnosis rate could be improved. Therefore, early diagnosis is important for malignant hematologic disease at molecular level...
October 2016: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/27761210/the-relationship-between-risk-factors-and-survival-in-adult-acute-lymphoblastic-leukemia
#12
Abolghasem Allahyari, Seyed-Mehdi Hashemi, Fahimeh Nazemian, Mohammad Karimi, Mohammad-Reza Kazemi, Masoud Sadeghi
BACKGROUND: Acute lymphoblastic leukemia (ALL) is aggressive cancer, especially in adults as only 20-40% is cured with current treatment regimens. OBJECTIVES: The aim of this study is to evaluate prognostic factors and their effects on survival in ALL patients in the Northeast of Iran. METHODS: In a descriptive and retrospective study from 2009 to 2015, 48 ALL patients referred to hematology-oncology clinic. Age, sex, fever, blood group, type of ALL and consumption of amphotericin B, forms of cytogenetic, survival in the patients, WBC, hemoglobin, and platelet were checked in the first referral for every patient...
August 2016: Iranian Journal of Cancer Prevention
https://www.readbyqxmd.com/read/27751743/nutriscore-a-new-nutritional-screening-tool-for-oncological-outpatients
#13
Lorena Arribas, Laura Hurtós, Maria José Sendrós, Inmaculada Peiró, Neus Salleras, Eduard Fort, Jose Manuel Sánchez-Migallón
OBJECTIVES: The aim of this study was to design a new nutritional screening tool (NUTRISCORE) to detect nutritional risk in outpatients with cancer. METHODS: A multicenter, cross-sectional study was conducted. We randomly selected outpatients receiving onco-specific, palliative, or symptomatic treatment for malignant neoplasms (including solid tumors and hematologic malignancies). These patients were assessed using the NUTRISCORE tool, the Malnutrition Screening Tool (MST), and the Patient-Generated Subjective Global Assessment (PG-SGA) to detect risk for malnutrition...
January 2017: Nutrition
https://www.readbyqxmd.com/read/27749799/making-improvements-in-the-ed-does-ed-busyness-affect-time-to-antibiotics-in-febrile-pediatric-oncology-patients-presenting-to-the-emergency-department
#14
Christopher A Benner, Erika Mora, Emily Mueller, F Jacob Seagull, Kelly Walkovich, Kaleena Johnson, Schuyler Halverson, Ed Rothman, George Hucks, John G Younger, Michele M Nypaver
OBJECTIVES: Febrile neutropenic pediatric patients are at heightened risk for serious bacterial infections, and rapid antibiotic administration (in <60 minutes) improves survival. Our objectives were to reduce the time-to-antibiotic (TTA) administration and to evaluate the effect of overall emergency department (ED) busyness on TTA. METHODS: This study was a quality improvement initiative with retrospective chart review to reduce TTA in febrile children with underlying diagnosis of cancer or hematologic immunodeficiency who visited the pediatric ED...
October 4, 2016: Pediatric Emergency Care
https://www.readbyqxmd.com/read/27737963/long-term-single-institute-experience-with-trimodal-bladder-preserving-therapy-with-proton-beam-therapy-for-muscle-invasive-bladder-cancer
#15
Ei-Ichiro Takaoka, Jun Miyazaki, Hitoshi Ishikawa, Koji Kawai, Tomokazu Kimura, Ryutaro Ishitsuka, Takahiro Kojima, Reiko Kanuma, Daichi Takizawa, Toshiyuki Okumura, Hideyuki Sakurai, Hiroyuki Nishiyama
OBJECTIVE: We retrospectively elucidated the oncological outcomes, prognostic factors and toxicities of proton beam therapy in trimodal bladder-preserving therapy for muscle-invasive bladder cancer at our institution. METHODS: From 1990 to 2015, 70 patients with cT2-3N0M0 muscle-invasive bladder cancer underwent trimodal bladder-preserving therapy consisting of maximal transurethral resection of the bladder tumor, small pelvis photon irradiation, intra-arterial chemotherapy and proton beam therapy...
October 13, 2016: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27736871/determinants-of-treatment-abandonment-in-childhood-cancer-results-from-a-global-survey
#16
Paola Friedrich, Catherine G Lam, Geetinder Kaur, Elena Itriago, Raul C Ribeiro, Ramandeep S Arora
BACKGROUND: Understanding and addressing treatment abandonment (TxA) is crucial for bridging the pediatric cancer survival gap between high-income (HIC) and low-and middle-income countries (LMC). In childhood cancer, TxA is defined as failure to start or complete curative cancer therapy and known to be a complex phenomenon. With rising interest on causes and consequences of TxA in LMC, this study aimed to establish the lay-of-the-land regarding determinants of TxA globally, perform and promote comparative research, and raise awareness on this subject...
2016: PloS One
https://www.readbyqxmd.com/read/27730654/concomitant-use-of-direct-acting-antivirals-and-chemotherapy-in-hepatitis-c-virus-infected-patients-with-cancer
#17
M P Economides, P Mahale, A Kyvernitakis, F Turturro, H Kantarjian, A Naing, J Hosry, T L Shigle, A Kaseb, H A Torres
BACKGROUND: Antiviral therapy improves hepatic outcomes in hepatitis C virus (HCV)-infected cancer patients. However, such patients are not treated simultaneously with antivirals and chemotherapy, owing to overlapping toxicities with previous standard of care treatment of pegylated interferon and ribavirin. AIM: To examine the safety and clinically-significant drug-drug interactions observed in patients who received simultaneous treatment with direct-acting antivirals (DAAs) and chemotherapy...
December 2016: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27724969/survival-outcomes-in-patients-with-oropharyngeal-cancer-treated-with-carboplatin-paclitaxel-and-concurrent-radiotherapy
#18
M Roskies, E Kay-Rivest, M A Mascarella, K Sultanem, A Mlynarek, M Hier
BACKGROUND: A commonly employed treatment for advanced staged oropharyngeal squamous cell carcinoma (OPSCC) is concurrent radiation and chemotherapy with cisplatin as the gold standard. Carboplatin is reported to have the same radiopotentiation properties and a superior side effect profile; however, its use in head and neck cancer has been limited due to the paucity of data and reported hematologic side effects. In this study, we describe our institution's experience with carboplatin, paclitaxel and radiation in the treatment of oropharyngeal squamous cell carcinoma over a 10 year period...
October 10, 2016: Journal of Otolaryngology—Head & Neck Surgery
https://www.readbyqxmd.com/read/27719714/-the-consensus-of-the-diagnosis-and-treatment-of-primary-light-chain-amyloidosis-in-china-2016-version
#19
(no author information available yet)
No abstract text is available yet for this article.
September 14, 2016: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://www.readbyqxmd.com/read/27719713/-the-consensus-of-the-diagnosis-and-treatment-of-mantle-cell-lymphoma-in-china-2016-version
#20
(no author information available yet)
No abstract text is available yet for this article.
September 14, 2016: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
keyword
keyword
73361
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"